Kura Oncology(KURA)
搜索文档
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Newsfilter· 2024-04-22 19:30
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been gra ...
Kura Oncology(KURA) - 2023 Q4 - Earnings Call Transcript
2024-02-28 11:19
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Pete De Spain - Executive Vice President of Investor Relations Troy Wilson - President & CEO Tom Doyle - SVP of Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Li Watsek - Cantor Fitzgerald Peter Lawson - Barclays Justin Zelin - BTIG Reni Benjamin - Citizens JMP Brad Canino - Stifel Eva Privitera - TD Cowen Operator Good aft ...
Kura Oncology(KURA) - 2023 Q4 - Earnings Call Presentation
2024-02-28 09:36
业绩总结 - 公司目标是提供长期持久缓解机会,特别是针对急性白血病[5] - 公司拥有Menin抑制剂项目(Ziftomenib),有望通过单药和组合治疗解决高达50%的急性白血病病例[5] - Tipifarnib和KO-2806等Farnesyl转移酶抑制剂项目显示出持久的疗效[5] - 公司获得来自Bristol Myers Squibb的2,500万美元战略股权投资[5] - 公司现金储备高达5.7亿美元,可支持公司运营至2027年[5] 产品和技术研发 - Ziftomenib在急性白血病治疗中展现出潜在的核心作用[10] - Ziftomenib针对Menin-KMT2A途径,是急性白血病的基础靶点[11] - Ziftomenib在NPM1-m相位1a + 1b患者中表现出高度差异化的单药活性,CR率为40%[16] - Ziftomenib在KMT2A-r相位1a + 1b患者中的CR率为11.1%,MRD阴性率为100%[16] 市场扩张和并购 - Ziftomenib在AML和其他领域具有数十亿美元的潜在机会[32] 其他新策略和有价值的信息 - 公司领导团队和董事会经验丰富[6][7] - Ziftomenib单药治疗在KOMET-001临床试验中表现出鼓舞人心的安全性和耐受性[19] - Tipifarnib在HRAS突变HNSCC患者中显示出临床益处[36] - KO-2806与Cabozantinib在ccRCC模型中展示出协同作用[41]
Kura Oncology(KURA) - 2023 Q4 - Annual Report
2024-02-28 05:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 61-1547851 (State or other jurisdiction of ...
Kura Oncology(KURA) - 2023 Q3 - Earnings Call Transcript
2023-11-04 04:12
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Pete De Spain - Head of Investor Relations Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President of Finance & Accounting Conference Call Participants Jason Zemansky - Bank of America Peter Lawson - Barclays Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Jeet Mukherjee - BTIG Phil Nadeau - TD Cowen Brad Canino - Stifel Operator Good afternoon, ladies and gent ...
Kura Oncology(KURA) - 2023 Q3 - Earnings Call Presentation
2023-11-03 09:38
DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Cor ...
Kura Oncology(KURA) - 2023 Q3 - Quarterly Report
2023-11-03 04:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (Sta ...
Kura Oncology(KURA) - 2023 Q2 - Quarterly Report
2023-08-10 04:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (State or ...
Kura Oncology(KURA) - 2023 Q2 - Earnings Call Transcript
2023-08-06 22:41
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President, Investor Relations & Corporate Communications Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President, Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Roger Song - Jefferies Peter Lawson - Barclays Li Watsek - Cantor Bijan Mekoba - Stifel Julian Harrison - BTIG Reni Benjamin - JMP Securities Op ...
Kura Oncology (KURA) Investor Presentation - Slideshow
2023-05-18 23:25
DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Corporate Presentation – May 2023 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive th ...